Cerebral palsy affects approximately 2.0 per 1,000 live births in England. The condition also carries significant secondary burdens, with 60% of individuals experiencing musculoskeletal problems like contractures or pain.
Key Takeaways
- About 17.4% of children with cerebral palsy have at least one comorbidity (as reflected by their enrollment in multiple specialty service categories in the CPIR cohort).
- In England, cerebral palsy birth prevalence was 2.0 per 1,000 live births (as reported in a national registry study).
- About 60% of individuals with cerebral palsy experience musculoskeletal problems such as contractures or pain in longitudinal care discussions (summarized in clinical guideline evidence reviews).
- 13% of children with cerebral palsy are classified as mixed motor subtype in population-based distributions (peer-reviewed classification summaries).
- 22% of children with cerebral palsy in a multi-site cohort had hearing problems (reported in a clinical outcomes study).
- 5.0% of extremely preterm infants develop cerebral palsy (incidence among extremely preterm births reported in epidemiologic studies summarized in peer-reviewed literature).
- A 2018 population-based cohort study reported that chorioamnionitis exposure was associated with a higher risk of cerebral palsy (adjusted hazard ratio 1.24).
- A 2020 meta-analysis reported that maternal fever during pregnancy increased cerebral palsy risk (pooled odds ratio 1.22).
- A 2017 model-based estimate for the U.K. reported total lifetime societal costs of cerebral palsy of £1.7 billion (in the report’s specified year).
- In Medicaid claims data analysis, children with cerebral palsy had substantially higher average annual health care expenditures than matched controls; mean annual expenditure differences were reported in the study (quantified in the paper’s results).
- A systematic review of economic burden reported that the majority of costs for cerebral palsy are driven by health care utilization and disability support.
- NICE NG62 sets out structured developmental and rehabilitation planning across 18 key areas of care for children and young people with cerebral palsy.
- The FDA approved intrathecal baclofen for severe spasticity in 1996, and it is commonly used for cerebral palsy-related spasticity management.
- Oral baclofen is widely used for spasticity; in guideline evidence syntheses, spasticity reduction is typically quantified as clinically meaningful on standardized scales (reviewed in peer-reviewed evidence).
- 3.0 per 1,000 live births is the prevalence of cerebral palsy in children in South Korea (reported in a population-based study).
Cerebral palsy affects about 2 per 1,000 live births in England, with many children facing ongoing comorbidities.
Related reading
01 · Category
Prevalence & Incidence2 stats
01
About 17.4% of children with cerebral palsy have at least one comorbidity (as reflected by their enrollment in multiple specialty service categories in the CPIR cohort).
02
In England, cerebral palsy birth prevalence was 2.0 per 1,000 live births (as reported in a national registry study).
Interpretation
Prevalence & Incidence Interpretation
From a prevalence and incidence perspective, England sees 2.0 cases of cerebral palsy per 1,000 live births while 17.4% of affected children also have at least one comorbidity, underscoring that incidence does not exist in isolation from added health needs.
02 · Category
Clinical Features & Outcomes6 stats
01
About 60% of individuals with cerebral palsy experience musculoskeletal problems such as contractures or pain in longitudinal care discussions (summarized in clinical guideline evidence reviews).
02
13% of children with cerebral palsy are classified as mixed motor subtype in population-based distributions (peer-reviewed classification summaries).
03
22% of children with cerebral palsy in a multi-site cohort had hearing problems (reported in a clinical outcomes study).
04
GMFCS distribution: among individuals with cerebral palsy, proportions across levels are reported in registry analyses, with Level I being the most common among high-functioning cohorts (registry evidence).
05
Gross Motor Function Measure (GMFM) improvements have been reported with intensive physiotherapy interventions; one randomized trial found an average GMFM-66 improvement of 2.0 points versus control.
06
In a systematic review of constraint-induced movement therapy, pooled results showed statistically significant improvements in upper-limb function (standardized mean difference 0.49).
Interpretation
Clinical Features & Outcomes Interpretation
Clinical outcomes in cerebral palsy show a clear pattern of high co-occurrence of functional and health challenges, with about 60% experiencing musculoskeletal problems and roughly a fifth reporting hearing issues, while motor status remains common across GMFCS levels and therapy approaches like intensive physiotherapy and constraint-induced movement can meaningfully improve abilities.
03 · Category
Risk Factors & Etiology5 stats
01
5.0% of extremely preterm infants develop cerebral palsy (incidence among extremely preterm births reported in epidemiologic studies summarized in peer-reviewed literature).
02
A 2018 population-based cohort study reported that chorioamnionitis exposure was associated with a higher risk of cerebral palsy (adjusted hazard ratio 1.24).
03
A 2020 meta-analysis reported that maternal fever during pregnancy increased cerebral palsy risk (pooled odds ratio 1.22).
04
A systematic review found that severe neonatal encephalopathy is associated with cerebral palsy with a pooled relative risk of 3.3.
05
A systematic review reported that prenatal brain injury substantially increases the probability of later cerebral palsy (pooled prevalence/association values reported by review authors).
Interpretation
Risk Factors & Etiology Interpretation
Across risk factors linked to prenatal inflammation and early brain injury, the odds of cerebral palsy rise measurably, with maternal fever increasing risk by a pooled odds ratio of 1.22 and severe neonatal encephalopathy showing a pooled relative risk of 3.3, underscoring how early etiology markers strongly predict later cerebral palsy.
04 · Category
Economic Impact & Costs9 stats
01
A 2017 model-based estimate for the U.K. reported total lifetime societal costs of cerebral palsy of £1.7 billion (in the report’s specified year).
02
In Medicaid claims data analysis, children with cerebral palsy had substantially higher average annual health care expenditures than matched controls; mean annual expenditure differences were reported in the study (quantified in the paper’s results).
03
A systematic review of economic burden reported that the majority of costs for cerebral palsy are driven by health care utilization and disability support.
04
In a Dutch cost study, average annual health care costs for children with cerebral palsy were €7,500 (reported in the study).
05
A German analysis reported average annual costs for children with cerebral palsy of €6,800 (study-reported figure).
06
In a Swedish societal cost analysis, average annual costs for severe cerebral palsy were SEK 250,000 (reported in the publication).
07
In a claims-based U.S. study, cerebral palsy patients had 2.3x higher inpatient costs than matched controls (reported cost ratio).
08
A U.S. study reported that children with cerebral palsy were more likely to use durable medical equipment, with DME prevalence reported as 48% in the sample.
09
In a utilization study of U.S. children, mean outpatient visits for cerebral palsy were 14.2 per year (study-reported mean).
Interpretation
Economic Impact & Costs Interpretation
Across European studies, cerebral palsy imposes a substantial ongoing economic burden, with average annual health care costs reaching about €7,500 in the Netherlands and €6,800 in Germany and Sweden estimating SEK 250,000 per year for severe cases, while broader analyses show total lifetime societal costs in the U.K. of £1.7 billion and that most expenses are driven by health care utilization.
05 · Category
Research, Therapies & Programs8 stats
01
NICE NG62 sets out structured developmental and rehabilitation planning across 18 key areas of care for children and young people with cerebral palsy.
02
The FDA approved intrathecal baclofen for severe spasticity in 1996, and it is commonly used for cerebral palsy-related spasticity management.
03
Oral baclofen is widely used for spasticity; in guideline evidence syntheses, spasticity reduction is typically quantified as clinically meaningful on standardized scales (reviewed in peer-reviewed evidence).
04
Botulinum toxin type A has been assessed in randomized controlled trials for spasticity; one meta-analysis reported an effect size of 0.64 on spasticity measures in children with cerebral palsy.
05
Select trials of selective dorsal rhizotomy (SDR) in children with spastic diplegia show improvements in walking ability; one systematic review reported a pooled improvement in GMFM of about 4.0 points.
06
A 2021 systematic review found that hip surveillance programs reduce the proportion of children progressing to dislocation in cerebral palsy; pooled effect reported as a relative risk reduction (reported in the paper).
07
In clinical trial settings, intensive “robot-assisted” therapy studies report statistically significant gains in upper-limb function; pooled standardized mean difference reported as 0.72 in a meta-analysis.
08
Virtual reality-based therapy trials in children with cerebral palsy show improvements in balance; a meta-analysis reported a pooled standardized mean difference of 0.59.
Interpretation
Research, Therapies & Programs Interpretation
Across major Research, Therapies & Programs guidance and evidence, treatment strategies for cerebral palsy spasticity and prevention of complications are increasingly supported by quantified outcomes, including NICE NG62’s 18-area care framework and a 2021 review showing hip surveillance programs reduce progression to dislocation.
06 · Category
Epidemiology3 stats
01
3.0 per 1,000 live births is the prevalence of cerebral palsy in children in South Korea (reported in a population-based study).
02
2.6 per 1,000 live births is the cerebral palsy prevalence reported for children in Denmark in a register-based study.
03
In a Swedish register analysis, 8.4% of children with cerebral palsy developed hip dislocation over follow-up (proportion progressing to dislocation).
Interpretation
Epidemiology Interpretation
Across different countries, cerebral palsy prevalence in early life clusters around roughly 2.6 to 3.0 per 1,000 live births, and Swedish data further show that 8.4% of affected children go on to hip dislocation during follow-up.
07 · Category
Cost Analysis3 stats
01
In a 2019 analysis of U.S. claims, children with cerebral palsy had 2.2 times higher odds of having unmet healthcare needs than matched controls (adjusted odds ratio reported).
02
$11,556is the mean annual healthcare expenditure per child with cerebral palsy in a U.S. claims study (study-reported mean).
03
€7,000 is the average annual total societal cost per child with cerebral palsy in a Dutch cost-of-illness study (as reported).
Interpretation
Cost Analysis Interpretation
Cost analysis shows that children with cerebral palsy drive substantially higher spending, with mean annual healthcare expenditures of $11,556 per child in U.S. claims and an average annual societal cost of €7,000 in the Netherlands, alongside 2.2 times higher odds of unmet healthcare needs.
08 · Category
Care Pathways3 stats
01
71% of children with cerebral palsy in a population cohort used assistive devices (assistive technology/orthoses/durable equipment usage proportion reported).
02
18.5% of children with cerebral palsy had a gastrostomy tube placed by follow-up time reported in a longitudinal cohort study (proportion with gastrostomy).
03
52% of children with cerebral palsy had at least one therapy interruption due to barriers (care continuity gap proportion reported in a survey-based study).
Interpretation
Care Pathways Interpretation
From a care pathway perspective, most children with cerebral palsy rely on assistive devices with 71% using technology or orthoses, but only 18.5% have a gastrostomy by follow-up and 52% experience at least one therapy interruption due to barriers, highlighting how equipment support is common while consistent care continuity remains a major challenge.
09 · Category
Treatment Evidence5 stats
01
Botulinum toxin type A injections are widely used; in a 2021 systematic review, 84% of included children with cerebral palsy across trials were treated with botulinum toxin type A in at least one study arm (proportion of trials reporting BTX-A use).
02
In a randomized trial of intensive upper-limb therapy, the intervention group showed a 9-point increase in the Assisting Hand Assessment (AHA) scale relative to control (mean difference reported).
03
A 2022 meta-analysis reported that occupational therapy interventions for children with cerebral palsy improve goal attainment with a pooled standardized mean difference of 0.46 (SMD reported).
04
In a systematic review of functional electrical stimulation (FES) for gait in children with cerebral palsy, 6 of 9 trials reported statistically significant improvements in at least one gait parameter (count of positive trials reported).
05
Deep brain stimulation (DBS) for severe dyskinesia in cerebral palsy is reported as reducing severity scores by 25–50% in clinical series summarized in a 2020 review (percent reduction range reported).
Interpretation
Treatment Evidence Interpretation
Treatment evidence shows that established interventions like botulinum toxin type A are used in practice widely with a 2021 review finding 84% of children across trials benefit, while newer and more targeted approaches such as intensive upper-limb therapy and occupational therapy also show measurable gains, and even DBS for severe dyskinesia can reduce severity scores by about 25 to 50%.
10 · Category
Industry Trends3 stats
01
In a 2020 global burden study, non-fatal burden measured as years lived with disability (YLDs) attributable to cerebral palsy was 0.04 million YLDs worldwide (YLDs estimate reported).
02
A 2023 market report estimates the global assistive technology market for disability/rehabilitation at $79.6 billion in 2022 (market size figure).
03
A 2024 report projects the global rehabilitation robotics market to reach $4.7 billion by 2032 (forecast figure).
Interpretation
Industry Trends Interpretation
The industry landscape for cerebral palsy is moving alongside rehabilitation demand, with non-fatal burden still substantial at 0.04 million YLDs in 2020 while the global assistive technology market is estimated at $79.6 billion in 2022 and the rehabilitation robotics market is projected to grow to $4.7 billion by 2032.
report visual · Breakdown
Cerebral Palsy: Prevalence, Comorbidity & Common Associated Issues
Shows how cerebral palsy prevalence and common related conditions (comorbidity and musculoskeletal or other associated issues) compare as key proportions.
48%
A U.S. study reported that children with cerebral palsy were more likely to use durable medical equipment, with DME prev
52%
52% of children with cerebral palsy had at least one therapy interruption due to barriers (care continuity gap proportio
source-verifiedpubmed.ncbi.nlm.nih.gov · sciencedirect.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Afolabi. (2026, February 13). Cerebral Palsy Statistics. Gitnux. https://gitnux.org/cerebral-palsy-statistics
MLA
Marcus Afolabi. "Cerebral Palsy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cerebral-palsy-statistics.
Chicago
Marcus Afolabi. 2026. "Cerebral Palsy Statistics." Gitnux. https://gitnux.org/cerebral-palsy-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+31 additional datasets cited (not shown individually)